OUR SOLUTION APPROACH AGAINST SARS-CoV-2
IML-206 as a broad-spectrum antiviral drug for the treatment of patients infected with SARS-CoV-2 or other (future) coronaviruses. Unlike many other developments, the innovative substance IML-206 blocks specific cellular structures in humans, which are very likely indispensable for the replication of a broad range of coronavirus variants.
OUR SOLUTION APPROACH AGAINST HIV RESISTANCES
IML-106 for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Am Borsigturm 100, Berlin,berlin 13507,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://immunologik.de
- HQ
- Berlin, Berlin
Immunologik Gmbh Questions
Immunologik Gmbh's website is http://immunologik.de
Immunologik Gmbh's LinkedIn profile is https://de.linkedin.com/company/immunologik
Immunologik Gmbh has
2 employees.
View email and phone details for 2
employees at Immunologik Gmbh.
Immunologik Gmbh's industry is
Biotechnology Research
Immunologik Gmbh's top competitors are
Merlion Pharmaceuticals Gmbh,
Nordmark Pharma Gmbh,
Aav Gene Therapeutics,
Autolomous,
Cellphenomics Gmbh,
Atlas Life Sciences Gmbh I.g.,
Clearcut Medical Ltd.,
Tacalyx Gmbh,
Ceidos,
3b Pharmaceuticals Gmbh.
Immunologik Gmbh's categories are Biotechnology Research
Immunologik Gmbh's founding year is 2012
